Curcumin	curcumin	S_chemical	O
ameliorates	ameliorates	O	O
cognitive	cognitive	O	B_disease
dysfunction	dysfunction	O	I_disease
and	and	O	O
oxidative	oxidative	O	B_disease
damage	damage	O	I_disease
in	in	O	O
phenobarbitone	phenobarbitone	S_chemical	O
and	and	O	O
carbamazepine	carbamazepine	S_chemical	O
administered	administered	O	O
rats	rats	O	O
.	.	O	O

The	the	O	O
antiepileptic	antiepileptic	O	O
drugs	drugs	O	O
,	,	O	O
phenobarbitone	phenobarbitone	S_chemical	O
and	and	O	O
carbamazepine	carbamazepine	S_chemical	O
are	are	O	O
well	well	O	O
known	known	O	O
to	to	O	O
cause	cause	O	O
cognitive	cognitive	O	B_disease
impairment	impairment	O	I_disease
on	on	O	O
chronic	chronic	O	O
use	use	O	O
.	.	O	O

The	the	O	O
increase	increase	O	O
in	in	O	O
free	free	O	O
radical	radical	O	O
generation	generation	O	O
has	has	O	O
been	been	O	O
implicated	implicated	O	O
as	as	O	O
one	one	O	O
of	of	O	O
the	the	O	O
important	important	O	O
mechanisms	mechanisms	O	O
of	of	O	O
cognitive	cognitive	O	B_disease
impairment	impairment	O	I_disease
by	by	O	O
antiepileptic	antiepileptic	O	O
drugs	drugs	O	O
.	.	O	O

Curcumin	curcumin	S_chemical	O
has	has	O	O
shown	shown	O	O
antioxidant	antioxidant	O	O
,	,	O	O
anti-inflammatory	anti-inflammatory	O	O
and	and	O	O
neuro-protective	neuro-protective	O	O
properties	properties	O	O
.	.	O	O

Therefore	therefore	O	O
,	,	O	O
the	the	O	O
present	present	O	O
study	study	O	O
was	was	O	O
carried	carried	O	O
out	out	O	O
to	to	O	O
investigate	investigate	O	O
the	the	O	O
effect	effect	O	O
of	of	O	O
chronic	chronic	O	O
curcumin	curcumin	S_chemical	O
administration	administration	O	O
on	on	O	O
phenobarbitone-	phenobarbitone-	S_chemical	O
and	and	O	O
carbamazepine-induced	carbamazepine-induced	O	O
cognitive	cognitive	O	B_disease
impairment	impairment	O	I_disease
and	and	O	O
oxidative	oxidative	O	B_disease
stress	stress	O	I_disease
in	in	O	O
rats	rats	O	O
.	.	O	O

Pharmacokinetic	pharmacokinetic	O	O
interactions	interactions	O	O
of	of	O	O
curcumin	curcumin	S_chemical	O
with	with	O	O
phenobarbitone	phenobarbitone	S_chemical	O
and	and	O	O
carbamazepine	carbamazepine	S_chemical	O
were	were	O	O
also	also	O	O
studied	studied	O	O
.	.	O	O

Vehicle/drugs	vehicle/drugs	O	O
were	were	O	O
administered	administered	O	O
daily	daily	O	O
for	for	O	O
21days	21days	O	O
to	to	O	O
male	male	O	O
Wistar	wistar	O	O
rats	rats	O	O
.	.	O	O

Passive	passive	O	O
avoidance	avoidance	O	O
paradigm	paradigm	O	O
and	and	O	O
elevated	elevated	O	O
plus	plus	O	O
maze	maze	O	O
test	test	O	O
were	were	O	O
used	used	O	O
to	to	O	O
assess	assess	O	O
cognitive	cognitive	O	O
function	function	O	O
.	.	O	O

At	at	O	O
the	the	O	O
end	end	O	O
of	of	O	O
study	study	O	O
period	period	O	O
,	,	O	O
serum	serum	O	O
phenobarbitone	phenobarbitone	S_chemical	O
and	and	O	O
carbamazepine	carbamazepine	S_chemical	O
,	,	O	O
whole	whole	O	O
brain	brain	O	O
malondialdehyde	malondialdehyde	S_chemical	O
and	and	O	O
reduced	reduced	B_chemical	O
glutathione	glutathione	S_chemical	O
levels	levels	O	O
were	were	O	O
estimated	estimated	O	O
.	.	O	O

The	the	O	O
administration	administration	O	O
of	of	O	O
phenobarbitone	phenobarbitone	S_chemical	O
and	and	O	O
carbamazepine	carbamazepine	S_chemical	O
for	for	O	O
21days	21days	O	O
caused	caused	O	O
a	a	O	O
significant	significant	O	O
impairment	impairment	O	O
of	of	O	O
learning	learning	O	O
and	and	O	O
memory	memory	O	O
as	as	O	O
well	well	O	O
as	as	O	O
an	an	O	O
increased	increased	O	O
oxidative	oxidative	O	B_disease
stress	stress	O	I_disease
.	.	O	O

Concomitant	concomitant	O	O
curcumin	curcumin	S_chemical	O
administration	administration	O	O
prevented	prevented	O	O
the	the	O	O
cognitive	cognitive	O	B_disease
impairment	impairment	O	I_disease
and	and	O	O
decreased	decreased	O	O
the	the	O	O
increased	increased	O	O
oxidative	oxidative	O	B_disease
stress	stress	O	I_disease
induced	induced	O	O
by	by	O	O
these	these	O	O
antiepileptic	antiepileptic	O	O
drugs	drugs	O	O
.	.	O	O

Curcumin	curcumin	S_chemical	O
co-administration	co-administration	O	O
did	did	O	O
not	not	O	O
cause	cause	O	O
any	any	O	O
significant	significant	O	O
alteration	alteration	O	O
in	in	O	O
the	the	O	O
serum	serum	O	O
concentrations	concentrations	O	O
of	of	O	O
both	both	O	O
phenobarbitone	phenobarbitone	S_chemical	O
as	as	O	O
well	well	O	O
as	as	O	O
carbamazepine	carbamazepine	S_chemical	O
.	.	O	O

These	these	O	O
results	results	O	O
show	show	O	O
that	that	O	O
curcumin	curcumin	S_chemical	O
has	has	O	O
beneficial	beneficial	O	O
effect	effect	O	O
in	in	O	O
mitigating	mitigating	O	O
the	the	O	O
deterioration	deterioration	O	O
of	of	O	O
cognitive	cognitive	O	B_disease
functions	functions	O	I_disease
and	and	O	O
oxidative	oxidative	O	B_disease
damage	damage	O	I_disease
in	in	O	O
rats	rats	O	O
treated	treated	O	O
with	with	O	O
phenobarbitone	phenobarbitone	S_chemical	O
and	and	O	O
carbamazepine	carbamazepine	S_chemical	O
without	without	O	O
significantly	significantly	O	O
altering	altering	O	O
their	their	O	O
serum	serum	O	O
concentrations	concentrations	O	O
.	.	O	O

The	the	O	O
findings	findings	O	O
suggest	suggest	O	O
that	that	O	O
curcumin	curcumin	S_chemical	O
can	can	O	O
be	be	O	O
considered	considered	O	O
as	as	O	O
a	a	O	O
potential	potential	O	O
safe	safe	O	O
and	and	O	O
effective	effective	O	O
adjuvant	adjuvant	O	O
to	to	O	O
phenobarbitone	phenobarbitone	S_chemical	O
and	and	O	O
carbamazepine	carbamazepine	S_chemical	O
therapy	therapy	O	O
in	in	O	O
preventing	preventing	O	O
cognitive	cognitive	O	B_disease
impairment	impairment	O	I_disease
associated	associated	O	B_disease
with	with	O	I_disease
these	these	O	O
drugs	drugs	O	O
.	.	O	O

